Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Katherine Young

Physician Assistant Centennial, CO Physician Assistant

NPI 1760417299 CMS profile 811782

7030 S Yosemite St, Centennial, CO 80112

Open in the dashboard

General payments

$8,362

443 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Katherine Young of Centennial, CO is reported in the CMS Open Payments database as having received $8,362 across 443 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,307 66
2024 General $1,552 77
2023 General $1,912 99
2022 General $1,591 90
2021 General $2,000 111

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katherine Young
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Katherine Young were reported at $1,307. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Katherine Young Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,000 $132 $37–$438 $132
2022 $1,591 $155 $48–$522 $149
2023 $1,912 $167 $52–$557 $160
2024 $1,552 $178 $55–$600 $164
2025 $1,307 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,802 155 payments
  2. Novo Nordisk Inc $628 34 payments
  3. AstraZeneca Pharmaceuticals LP $567 30 payments
  4. Amgen Inc. $382 18 payments
  5. GlaxoSmithKline, LLC. $294 14 payments
  6. Pfizer Inc. $271 13 payments
  7. Lilly USA, LLC $251 14 payments
  8. Biogen, Inc. $231 7 payments
  9. Astellas Pharma US Inc $213 8 payments
  10. ITI, Inc. $210 11 payments
  11. Other $2,513 139 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,300 442 payments
  2. Education $62 1 payment
Products named General payments · program years 2021–2025
  1. UBRELVY $1,292 73 payments
  2. VRAYLAR Neuroscience $950 51 payments
  3. SYNTHROID $380 25 payments
  4. Ozempic $311 16 payments
  5. RYBELSUS $311 16 payments
  6. Otezla $298 14 payments
  7. QULIPTA $277 13 payments
  8. Repatha $264 12 payments
  9. NURTEC ODT $200 10 payments
  10. VRAYLAR Neuroscience $189 8 payments
  11. Other $5,297 287 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

1,694

Median for Physician Assistant: 241

Drug cost

$45,116

Median for Physician Assistant: $4,110

Branded share of claims

29.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Progesterone Progesterone, Micronized Brand 126 $10,108
Symbicort Budesonide/Formoterol Fumarate Brand 17 $5,867
Bupropion Xl Bupropion Hcl Brand 28 $4,734
Synthroid Levothyroxine Sodium Brand 45 $4,718
Liothyronine Sodium Generic 71 $2,765
Estradiol (Twice Weekly) Estradiol Brand 21 $1,740
Levothyroxine Sodium Generic 135 $1,210
Atorvastatin Calcium Generic 155 $1,164
Omeprazole Generic 45 $875
Albuterol Sulfate Hfa Albuterol Sulfate Brand 17 $783

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $232
$232 — —
UBRELVY
  • AbbVie, Inc. $125
$125 — —
QULIPTA
  • AbbVie, Inc. $90
$90 — —
NURTEC ODT
  • PFIZER INC. $56
$56 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

443 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record